A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with
or without ramucirumab as first line therapy in participants with metastatic gastric or
gastroesophageal junction (GEJ) adenocarcinoma.